The global drug delivery technology market is expected to be valued at USD 43.9 billion in 2023. Increasing adoption of advanced technology for effectively delivering the drug to the target site is expected to drive overall market growth. The overall demand for drug delivery technology is projected to grow at a CAGR of 12.6% between 2023 and 2033, totaling around 143.5 billion by 2033.
A drug delivery system is a process of administering a therapeutic substance through the common route of administration to achieve a therapeutic effect in humans or animals. Drugs release the active ingredients in the target area that it controls through their formulation in the period.
The most important driving factor for the drug delivery technology market is the increasing demand for effective delivery mechanisms of novel biopharmaceuticals.
Recently, AstraZeneca signed a licensing agreement with Starpharma to use its DEP drug delivery technology, aiming to enhance pharmaceuticals' dosing and efficacy characteristics. AstraZeneca agreed to fund all development and commercialization costs, including ongoing and future collaborative work with Starpharma.
| Attribute | Details |
|---|---|
| Market CAGR (2023 to 2033) | 12.6% |
| Market Valuation (2023) | USD 43.9 billion |
| Market Valuation (2033) | USD 143.5 billion |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Growing incidence of chronic diseases such as cardiovascular diseases, diabetes, and cancer, technological advancement, innovation, the growing focus on pediatric and geriatric patients, changes in lifestyle due to growing urbanization, and the increasing demand for minimally invasive surgeries are the most important driving factors in drug delivery technology market. Since the growth of the biopharmaceutical market is fast, the demand for the drug delivery technology market has increased.
With so many advantages and splendid features of drug delivery technology, it has a few disadvantages too. Side effects related to drugs, patent expiry, and regulatory hurdles are key barriers to drug delivery technology.
Rising Prevalence of Chronic Diseases & Surplus Investments in R&D to Act as Primary Growth Drivers
Growing incidence of chronic diseases such as cardiovascular diseases, diabetes, and cancer, technological advancement, innovation, the growing focus on pediatric and geriatric patients, changes in lifestyle due to growing urbanization, and the increasing demand for minimally invasive surgeries, are the most important driving factors in the global market.
Since the growth of the biopharmaceutical market is fast, the demand for the drug delivery technology market has increased.
Swelling demand for novel drug delivery devices is expected to advance R&D in the field. Key market players perpetually engage in strategic alliances to develop advanced technology for various applications.
In January 2021, AstraZeneca collaborated with Aptamer Group, a biotechnology company, to explore its technology to develop a novel drug-delivery device for a kidney. In addition, the increasing adoption of drug-delivery devices in home-care settings is snowballing the accessibility of these devices for patients.
Principal Consultant
Uncontrolled Intake of Medicine May Lead to Certain Side Effects Likely to Impede Market Growth.
Despite the advantages and advancements of these drug delivery devices, certain challenges are expected to hinder market growth. The major challenge faced with this drug delivery device is its inefficiency in delivering poorly soluble drugs.
Furthermore, other bioavailability hurdles of poorly soluble drugs are also expected to impact market growth. In addition, these drug delivery devices may release uncontrolled drugs on the infection site, which can later lead to other side effects such as infections and allergies.
The global demand for drug delivery technology secured a CAGR of 8.6% between 2018 and 2022. The market captured a valuation of USD 26 billion in 2018 and USD 39.3 billion in 2022.
The drug delivery technology market has grown substantially at a healthy CAGR due to the growing incidence of chronic diseases and lifestyle changes. With rapid technological advancement and innovation, the drug delivery technology market is expected to grow globally.
In addition, the increasing prevalence of chronic diseases in regions like North America and Europe has boosted the demand for drug delivery technology. According to Rand.org, almost 60 percent of American adults with at least one chronic condition 42 percent have more than one.
They account for hundreds of billions of dollars in healthcare spending every year. Owing to these factors, the market for drug delivery technology is projected to experience exceptional growth over the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Based on the route of administration, the oral route of administration subtype captures the highest share in 2023. It is expected to be the fastest-growing segment of the Drug Delivery Technology market during the forecast period.
The oral drug delivery system comprises extensive dosage forms, including tablets, capsules, syrups, solutions, and suspensions. This segment also contains drug delivery products such as films and tablets. The oral route is the preferred route of administration regarding safety, ease of use, cost, and drug stability.
Inhalation drug delivery systems are ideal for pulmonary conditions such as asthma and Chronic Obstructive Pulmonary Disease (COPD). Aspects such as the growing prevalence of respiratory diseases and the technological development of devices used for inhalation delivery, such as nebulizers and inhalers, are anticipated to propel the growth of this segment.
The injectable route of administration is likely to expand at the fastest growth rate throughout the forecast period. Progressions in injectable drug delivery systems, such as the advent of prefilled syringes and pen injectors, have augmented the demand in the past two to three years.
Additionally, developing materials for syringes, such as polymers, which are inert to most chemicals, stimulates market growth.
| Countries | Forecast Share Between 2023 to 2033 |
|---|---|
| United States | 28.6% |
| Germany | 5.5% |
| Japan | 5.3% |
| Countries | Forecast CAGR Between 2023 to 2033 |
|---|---|
| Australia | 7.7% |
| China | 10.1% |
| India | 9.5% |
| United Kingdom | 8.8% |
Rising Awareness Regarding the Novel Advancements & Presence of Prominent Players to Put Region at the Forefront
Regarding regional platforms, North America holds a significant market share in the market. The region is expected to surge at over 33.6% share in 2023. It is projected to maintain its lead over the forecast period due to its preference for printing by thermal label manufacturers. The United States & Canada account for most of the regional revenue contribution.
This market growth is attributed to prominent regional players and the growing adoption of drug-delivery devices. Besides, rising awareness in the region regarding the advantages of drug delivery devices is also likely to boost the market growth in the region.
In addition, growing product approval in countries such as the United States is also projected to contribute to market growth. In March 2019, Aptar Pharma received USA FDA approval for a nasal drug delivery device.
The increasing burden of chronic diseases such as cancer, diabetes, and cardiac disorders is aiding the market growth. According to the American Diabetes Association (ADA), 34.2 million Americans had diabetes in 2020, of which 26.8 million were diagnosed and 7.3 million were undiagnosed. Consequently, an increasing number of diagnosed diabetes cases is anticipated to contribute toward adopting drug-delivery devices for diabetes.
Availability of Exceptional Healthcare Infrastructure to Boost Regional Revenue Share
According to Future Market Insights, Europe is expected to provide immense growth opportunities for Drug Delivery Technology and reach the highest share of 29.3% in 2023. This market growth is attributed to growing research and developmental activities and the presence of key pharmaceutical companies in the region.
With the significant surge in patients suffering from chronic diseases such as cancer, diabetes, and COPD, the regional market is subject to tread along a stellar growth track over the coming years.
In Nov 2021, Baxter International Inc., a global leader in sterile medication production and delivery, announced an approximately USD 100 million expansion of its sterile fill/finish manufacturing facility in Halle/Westfalen, Germany. Surplus investments by key players in research facilities have propelled the market growth for drug delivery technology.
Expanding Geriatric Population one of the Significant Causes of the Development of Drug Delivery Technology
As per the recent analysis by Future Market Insights, Asia Pacific is anticipated to be the highest-growing region over the forecast period. A large patient pool in countries like Japan, China, and India is also leading to the adoption of drug-delivery devices by several end-users.
In addition, in Japan, distinctive drug delivery devices are being introduced for delivering specific types of drugs.
In December 2019, the YpsoMate autoinjector was launched in the Japanese market to accurately deliver Teribone drug. Thus, the growing adoption of advanced drug delivery devices in the region is expected to boost market growth during the forecast period.
Also, regional players are doing mergers and acquisitions to expand their product portfolio and increase market reach. For instance, Pfizer Inc.
and Acuitas Therapeutics, a company focused on developing lipid nanoparticle (LNP) delivery systems to enable messenger RNA (mRNA)-based therapeutics, today announced they have entered into a Development and Option agreement under which Pfizer is estimated to have the option to license, on a non-exclusive basis, Acuitas’ LNP technology for up to 10 targets for vaccine or therapeutic development.
How are key players Opening Frontiers for Future Growth?
Many prominent market players in the global market are working hand-in-hand to provide the best-in-class Drug Delivery Technology for enhancing the global analytics arena.
However, many global startups in the global market are stepping forward to match the requirements of the Drug Delivery Technology domain.
What are the Leading Players in the Drug Delivery Technology Market Up to?
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Market Analysis | USD billion for Value |
| Key Countries Covered | United States, United Kingdom, Japan, India, China, Australia, Germany |
| Key Segments Covered | Route of Administration, End User, Region |
| Key Companies Profiled | Johnson and Johnson Pvt. Ltd; 3M; Novartis AG; Pfizer Inc.; GlaxoSmithKline PLC; Merck & Co. Inc.; Antares Pharma; Generex Biotechnology; Sivida Corporation; Alkermes; Aradigm Corp.; Vectura Group Plc.; NanoPass Technologies Ltd. |
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The global drug delivery technology market valuation is US$ 43.9 billion in 2023.
The global market is estimated to exceed US$ 143.5 billion by 2033, registering a 12.6% CAGR over the forecast period.
The market in India is experiencing robust growth, with a projected 9.5% CAGR through 2033.
Different types of drug delivery technologies in the market include oral drug delivery, injectable drug delivery, transdermal patches, and others.
Recent advancements encompass nanotechnology-based carriers, targeted drug delivery, and smart drug delivery systems.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 5.1. Oral Route 5.2. Parenteral Route 5.3. Intramuscular 5.4. Intravenous 5.5. Intra-arterial 5.6. Subcutaneous Route 5.7. Transdermal Route 5.8. Inhalation Route 5.9. Nasal Drug Delivery 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 6.1. Hospitals 6.2. Clinics 6.3. Diagnostic Centres 6.4. Home care settings 6.5. Others 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. North America 7.2. Latin America 7.3. Western Europe 7.4. Eastern Europe 7.5. South Asia and Pacific 7.6. East Asia 7.7. Middle East and Africa 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. Key Countries Market Analysis 16. Market Structure Analysis 17. Competition Analysis 17.1. Johnson and Johnson Pvt. Ltd 17.2. 3M 17.3. Novartis AG 17.4. Pfizer Inc. 17.5. GlaxoSmithKline PLC 17.6. Merck & Co. Inc. 17.7. Antares Pharma 17.8. Generex Biotechnology 17.9. Sivida Corporation 17.10. Alkermes 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Drug Delivery Technology Market
